Cantargia is a single-asset clinical-stage biotech; the FY2025 reported operating profit was entirely a one-off — the SEK 317m CAN10 out-licence to Otsuka (flagged a Key Audit Matter). On a recurring basis it loses money by design: adjusted NOPAT −SEK 154m, ROIC −66%, EP −SEK 173m. Balance-sheet returns are not the value gauge here — the enterprise is the off-balance-sheet pipeline.
The value case is two-legged optionality: lead antibody CAN04/nadunolimab in Phase 2 (promising PDAC/TNBC survival signals, FDA Fast Track), plus the retained economics on Otsuka's global CAN10 — up to USD 580–613m in milestones and low-double-digit royalties. The Otsuka deal is genuine validation and a non-dilutive funding bridge.
The constraint is cash and binarity: ~SEK 258m of funds against ~SEK 26m/quarter recurring burn gives roughly a 2–2.5-year runway, so a dilutive raise or a milestone is needed before the next value inflection. Outcomes are binary — a quality/value mandate cannot underwrite this at size.
The standard reverse-DCF / economic-profit frame does not apply: ROIC and EP are negative by design and IC is essentially the cash war-chest. The market prices the pipeline at ~SEK 225m enterprise (market cap SEK 483m less SEK 258m net cash) — a risk-adjusted option on Phase 2 data and Otsuka milestones.
Base SEK 2.10 (roughly the current risk-adjusted option value); bull SEK 6.00 if CAN04 Phase 2 delivers and Otsuka's CAN10 triggers milestones; bear SEK 0.80 on a trial miss or a dilutive rescue raise. The wide spread reflects the binary payoff, not a modelled intrinsic value.
Reverse-DCF panel unavailable: non-positive nopat.
| Scenario | 24m target | Upside | Prob. | Driver |
|---|---|---|---|---|
| Bull | SEK 6 | +209% | 20% | CAN04 Phase 2 delivers + Otsuka CAN10 milestones trigger |
| Base | SEK 2 | +8% | 45% | Current risk-adjusted pipeline option value |
| Bear | SEK 1 | -59% | 35% | Trial miss or dilutive rescue raise |
| Prob-weighted | SEK 2 | +25% | 100% | Scenario-weighted expected value |
Positive PDAC/TNBC survival data with FDA Fast Track would re-rate the equity multiples of the current option value.
Up to USD 580–613m milestones + low-double-digit royalties on CAN10 — a non-dilutive, big-pharma-validated upside stream.
~SEK 258m of funds (EV only SEK 225m) part-covers downside and buys ~2–2.5 years of runway.
A further out-licence of CAN04, on the CAN10 template, would fund development without heavy dilution.
Auditor-verified IFRS 15 treatment of the one-off; no accounting red flags to discount the option.
Cantargia is a pre-commercial biotech whose recurring economics are negative by design — ROIC/EP are not the value gauge. The case rests on off-balance-sheet optionality: CAN04 Phase 2 plus retained Otsuka CAN10 milestones/royalties, part-cushioned by ~SEK 258m net cash. Speculative HOLD, low conviction; base target SEK 2.10.
This does not clear the book's quality bar and should be sized as a small binary option, not a core holding. The next Phase 2 readout and any Otsuka milestone are the value-determining catalysts; a dilutive raise before them is the principal downside trigger.
Every adjustment traces to the cited note/page in the source filing — click to open it there. Annual report / 10-K: 📄 open · Latest interim: 📄 open
| Adjustment / figure | Value | Source | Why mttssn treats it this way |
|---|---|---|---|
| One-off Otsuka CAN10 revenue (removed in full) | 317 | FY IS p.38 (Net Sales 316,702) + Note 5/6 p.53 + Directors' Report p.29 + Auditor KAM p.63 📄 p.53 | FY2025 net sales 316,702 KSEK 'solely generated from the acquisition of the CAN10 program by Otsuka Pharmaceutical' (Note 5, verbatim). USD 33M upfront on divesting the CAN10 IL1RAP program; IFRS 15 point-in-time transfer ('control transferred, no remaining performance obligations', Note 2.10). 100% non-recurring — stripped in full to reveal the recurring loss. Encoded as other_one_off_addback = -316.7 (removing a non-recurring gain). |
| LTM reported operating result (before strip) | 162 | computed: FY op 154,100 + Q1'26 -36,891 - Q1'25 -45,032 📄 p.13 | LTM operating result 162,241 KSEK is a one-off artifact of the FY Otsuka gain; positive only because the 316.7M one-off sits inside the FY anchor. |
| Recurring LTM operating result / adjusted NOPAT | -154 | computed: LTM op 162.2 - one-off 316.7; tax = 0 📄 p.13 | 162.2M - 316.7M = -154.5M. This is the true recurring operating LOSS run-rate. Tax = 0 (unrecognised DTA, loss carryforwards) so adjusted NOPAT = recurring EBIT = -154.5M. |
| Q1 2026 operating result (recurring quarterly run-rate) | -36.9 | Q1 IS Operating result -36,891, p.13 📄 p.13 | Recurring quarterly operating LOSS -36,891 KSEK (vs -45,032 in Q1 2025 — R&D eased post-CAN10 handover). The clean recurring run-rate absent any one-off. |
| Q1 2026 total equity (IC base) | 234 | Q1 BS Total equity 233,951, p.14 📄 p.14 | Q1 2026 total equity 233,951 KSEK used as adjusted IC. No interest-bearing debt (25M loan repaid, 50M facility undrawn), no lease liabilities, no NCI, no OCI. IC = equity. |
| Q1 2026 cash + short-term investments (treated as operational) | 258 | Q1 BS p.14 (cash 246,034 + ST investments 12,000); Key Figures p.17 (Total available funds 258,034) 📄 p.17 | 246,034 cash + 12,000 fixed-income fund investments = 258,034 KSEK total available funds. CLINICAL-STAGE OVERRIDE: treated as fully operational (R&D runway), excess_cash forced to 0, so IC stays positive at ~equity and ROIC is legitimately negative rather than a false positive. |
| Q1 2026 recurring operating cash burn (runway basis) | -25.9 | Q1 Cash flow, 'Cash flow from operating activities' -25,909, p.16 📄 p.16 | Recurring operating cash burn -25,909 KSEK/quarter is the honest runway metric. Total change in cash -37,956 includes a one-time -12,000 reclassification into fixed-income funds (still available). On ~26M/q operating burn, 258M funds give ~2-2.5 yr runway absent financing/milestones — going-concern context. |